+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neutropenia Treatment Market by Treatment Type (Filgrastim, Lenograstim, Pegfilgrastim), Therapy Class (Biosimilar, Originator), Route Of Administration, Distribution Channel, End User, Patient Age Group, Severity - Global Forecast 2025-2030- Product Image
Neutropenia Treatment Market by Treatment Type (Filgrastim, Lenograstim, Pegfilgrastim), Therapy Class (Biosimilar, Originator), Route Of Administration, Distribution Channel, End User, Patient Age Group, Severity - Global Forecast 2025-2030- Product Image
Sale

Neutropenia Treatment Market by Treatment Type (Filgrastim, Lenograstim, Pegfilgrastim), Therapy Class (Biosimilar, Originator), Route Of Administration, Distribution Channel, End User, Patient Age Group, Severity - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674204
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Neutropenia treatment is advancing rapidly, fueled by innovation in biologics, supportive care, and tailored patient management. As healthcare providers and industry leaders adapt to shifting protocols and regulatory changes, understanding the dynamics of this evolving market is critical for sustaining growth and improving patient outcomes.

Market Snapshot: Neutropenia Treatment Market Growth and Trends

The Neutropenia Treatment Market grew from USD 15.08 billion in 2024 to USD 15.85 billion in 2025. It is expected to continue growing at a CAGR of 5.02%, reaching USD 20.24 billion by 2030. Market momentum is sustained by expanding adoption of advanced supportive therapies, biosimilars, and innovative delivery solutions across mature and emerging healthcare systems. Growth factors and digital health tools are transforming neutropenia care, as both clinicians and payers emphasize patient-centric strategies to optimize safety, efficacy, and resource utilization.

Scope & Segmentation: In-Depth View of the Neutropenia Treatment Market

This report provides a comprehensive analysis of the neutropenia treatment landscape, including detailed segmentation by product, patient, and channel categories. Covered dimensions include:

  • Treatment Types: Filgrastim (300 mcg, 480 mcg, 600 mcg), Lenograstim (3 mg, 5 mg), Pegfilgrastim (6 mg)
  • Therapy Classes: Biosimilar, Originator
  • Routes of Administration: Intravenous Injection, Subcutaneous Injection
  • Distribution Channels: Hospital Pharmacy (Inpatient, Outpatient), Online Pharmacy, Retail Pharmacy (Chain, Independent)
  • End Users: Ambulatory Care Centers, Clinics, Home Care, Hospitals (Private, Public)
  • Patient Age Groups: Adult, Geriatric, Pediatric
  • Severity Levels: Mild, Moderate, Severe
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including key markets such as United Kingdom, Germany, France, Russia, Saudi Arabia, South Africa, Denmark, Poland, Switzerland, Netherlands), and Asia-Pacific (China, India, Japan, Australia, South Korea, Thailand, Vietnam, among others)
  • Companies Explored: Amgen Inc., Sandoz International GmbH, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., Coherus BioSciences, Inc., Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Biocon Limited, Celltrion, Inc.

Key Takeaways: Strategic Insights for Senior Decision-Makers

  • Emerging therapies and novel biologics are reshaping clinical pathways, prioritizing tailored dosing and patient convenience to improve treatment adherence and outcomes.
  • The rise of biosimilars is intensifying competition among market players, prompting investment in value-driven patient support and real-world evidence initiatives.
  • Technological integration, such as digital health monitoring tools, supports proactive intervention and enables data-driven management across inpatient and outpatient settings.
  • Intravenous and subcutaneous administration routes are increasingly differentiated by care environment, balancing inpatient robustness and flexibility for home-based recovery.
  • Collaborative models between originators and regional innovators highlight the importance of localized production, co-development, and joint distribution for market access.
  • Disease severity, patient age, and healthcare infrastructure drive distinct approaches to therapy selection, procurement, and utilization in both developed and emerging markets.

Tariff Impact: Navigating Regulatory and Supply Chain Challenges

United States tariff adjustments anticipated in 2025 will affect the entire neutropenia treatment supply chain, from sourcing biologics to finished product distribution. Increased duties may challenge manufacturers on cost and procurement, driving a shift toward locally sourced intermediates and incentivizing scenario planning to maintain supply continuity. Hospitals and pharmacies are poised to adapt with alternative supplier strategies and enhanced contract management to sustain patient access in a shifting policy environment.

Methodology & Data Sources: Rigorous, Multi-Source Approach

This report applies a hybrid research framework, starting with interviews of key opinion leaders (hematologists, oncologists, clinical pharmacists) and primary surveys conducted with hospital and specialty pharmacy stakeholders. Extensive secondary research draws on peer-reviewed journals, regulatory filings, and corporate presentations. Continuous stakeholder engagement and data cross-validation reinforce analytical accuracy.

Why This Report Matters: Actionable Insight for Industry Leadership

  • Empowers strategic planning by clarifying evolving treatment and procurement trends.
  • Enables agile responses to regulatory and competitive disruptions across global and regional markets.
  • Supports informed investments in patient support, technology integration, and collaborative innovation to drive business growth and improve care standards.

Conclusion

Senior decision-makers gain an integrated perspective on neutropenia treatment trends, risks, and opportunities worldwide. With thorough coverage of product, regional, and operational determinants, this report offers a strong foundation for shaping future-ready strategies and operational resilience in the neutropenia care sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Market entry of pegfilgrastim on-body injector devices improving patient adherence
5.2. Rising adoption of biosimilar filgrastim products driving cost competitive dynamics
5.3. Development of oral granulocyte colony-stimulating factor analogs for outpatient use
5.4. Integration of pharmacogenomics for personalized neutropenia prophylaxis dosing strategies
5.5. Pipeline focus on CXCR4 antagonists for accelerated neutrophil recovery in transplant patients
5.6. Expansion of digital monitoring tools to track neutrophil counts and treatment compliance
5.7. Increased supportive care reimbursement policies boosting adoption of G-CSF therapies
5.8. Growth of emerging markets with rising chemotherapy-induced neutropenia incidence rates
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Neutropenia Treatment Market, by Treatment Type
8.1. Introduction
8.2. Filgrastim
8.2.1. 300 mcg
8.2.2. 480 mcg
8.2.3. 600 mcg
8.3. Lenograstim
8.3.1. 3 mg
8.3.2. 5 mg
8.4. Pegfilgrastim
8.4.1. 6 mg
9. Neutropenia Treatment Market, by Therapy Class
9.1. Introduction
9.2. Biosimilar
9.3. Originator
10. Neutropenia Treatment Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous Injection
10.3. Subcutaneous Injection
11. Neutropenia Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.2.1. Inpatient Pharmacy
11.2.2. Outpatient Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
11.4.1. Chain Pharmacy
11.4.2. Independent Pharmacy
12. Neutropenia Treatment Market, by End User
12.1. Introduction
12.2. Ambulatory Care Centers
12.3. Clinics
12.4. Home Care
12.5. Hospitals
12.5.1. Private
12.5.2. Public
13. Neutropenia Treatment Market, by Patient Age Group
13.1. Introduction
13.2. Adult
13.3. Geriatric
13.4. Pediatric
14. Neutropenia Treatment Market, by Severity
14.1. Introduction
14.2. Mild
14.3. Moderate
14.4. Severe
15. Americas Neutropenia Treatment Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Neutropenia Treatment Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Neutropenia Treatment Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Amgen Inc.
18.3.2. Sandoz International GmbH
18.3.3. Pfizer Inc.
18.3.4. Teva Pharmaceutical Industries Ltd.
18.3.5. Viatris Inc.
18.3.6. Coherus BioSciences, Inc.
18.3.7. Fresenius Kabi AG
18.3.8. Intas Pharmaceuticals Ltd.
18.3.9. Biocon Limited
18.3.10. Celltrion, Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. NEUTROPENIA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2024 VS 2030 (%)
FIGURE 18. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. NEUTROPENIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. NEUTROPENIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. NEUTROPENIA TREATMENT MARKET: RESEARCHAI
FIGURE 30. NEUTROPENIA TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 31. NEUTROPENIA TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 32. NEUTROPENIA TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. NEUTROPENIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 300 MCG, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 300 MCG, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 480 MCG, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 480 MCG, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 600 MCG, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 600 MCG, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 3 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 3 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 5 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 5 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 6 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 6 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY BIOSIMILAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ORIGINATOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ORIGINATOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MILD, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 155. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 156. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 157. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 158. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 159. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2024 (USD MILLION)
TABLE 160. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2025-2030 (USD MILLION)
TABLE 161. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 162. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 163. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 164. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 165. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 170. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 171. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 172. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 173. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 176. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 177. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 178. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 179. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
TABLE 180. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2025-2030 (USD MILLION)
TABLE 181. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 182. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 183. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 184. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 185. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2024 (USD MILLION)
TABLE 186. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2025-2030 (USD MILLION)
TABLE 187. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 188. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 189. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 190. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 191. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 196. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 197. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 198. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 199. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 202. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 203. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 204. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 205. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
TABLE 206. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 308. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 309. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 310. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 311. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
TABLE 312. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2025-2030 (USD MILLION)
TABLE 313. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 314. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 315. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 316. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 317. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2024 (USD MILLION)
TABLE 318. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2025-2030 (USD MILLION)
TABLE 319. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 320. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 321. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 322. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 323. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 324. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 325. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 326. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 327. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 328. GERMANY NEUTROPENIA TREATMENT MARKE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Neutropenia Treatment market report include:
  • Amgen Inc.
  • Sandoz International GmbH
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Coherus BioSciences, Inc.
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Ltd.
  • Biocon Limited
  • Celltrion, Inc.

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 15.85 Billion
Forecasted Market Value ( USD ) by 2030 $ 20.24 Billion
Compound Annual Growth Rate5.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Chemotherapy-Induced Neutropenia Treatment Global Market Report 2025 - Product Image

Chemotherapy-Induced Neutropenia Treatment Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 195 Pages
  • Global
From
Chemotherapy-Induced Neutropenia Treatment - Global Strategic Business Report - Product Image

Chemotherapy-Induced Neutropenia Treatment - Global Strategic Business Report

  • Report
  • 381 Pages
  • Global
From
Neutropenia Treatment Market Report by Treatment, Distribution channel, and Region 2025-2033 - Product Image

Neutropenia Treatment Market Report by Treatment, Distribution channel, and Region 2025-2033

  • Report
  • 143 Pages
  • Global
From
Febrile Neutropenia Drug Pipeline Analysis Report 2025 - Product Image

Febrile Neutropenia Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From

About the Neutropenia Drug Market

Neutropenia Drug is a type of drug used to treat immune disorders, specifically those that involve a decrease in the number of neutrophils, a type of white blood cell. Neutropenia can be caused by a variety of conditions, including chemotherapy, radiation therapy, and certain infections. Neutropenia drugs are designed to increase the number of neutrophils in the body, helping to reduce the risk of infection and other complications. These drugs are typically administered intravenously or orally, depending on the severity of the condition. The Neutropenia Drug market is highly competitive, with a number of companies offering products to treat this condition. Some of the major players in this market include Amgen, Novartis, Pfizer, Merck, and Roche. These companies offer a range of products, including monoclonal antibodies, cytokines, and other biologics. Additionally, there are a number of smaller companies that offer generic versions of these drugs. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.